DataSheet1_Safety of midodrine in patients with heart failure with reduced ejection fraction: a retrospective cohort study.PDF

Background: Heart failure with reduced ejection fraction (HFrEF) poses significant health risks. Midodrine for maintaining blood pressure in HFrEF, requires further safety investigation. This study explores midodrine’s safety in HFrEF through extensive matched analysis.Methods: Patients with HFrEF (LVEF Results: After 1:1 PSM, 5813 cases were included in each group. The midodrine group had higher risks of respiratory failure (HR: 1.16, 95% CI: 1.08–1.25), ICU admissions (HR: 1.14, 95% CI: 1.06–1.23), hospitalizations (HR: 1.21, 95% CI: 1.12–1.31), and mortality (HR: 1.090, 95% CI: 1.01–1.17). Interestingly, midodrine use reduced ER visits (HR: 0.77, 95% CI: 0.71–0.83). Similar patterns of lower ER visit risk and higher risks for ICU admissions, respiratory failure, and overall hospitalizations were observed in most subgroups.Conclusion: In this large-scale study, midodrine use was associated with reduced ER visits but increased risks of respiratory failure, prolonged ICU stays, higher hospitalizations, and elevated mortality in HFrEF patients. Further research is needed to clarify midodrine’s role in hemodynamic support and strengthen existing evidence.</p

Comparison of survival day before mortality in paraquat-poisoned patients with additional different combined immunosuppressive regimens and hemoperfusion.

<p>Cox regression analysis of mortality rates among different treatment groups, adjusted for age and sex, was used to calculate the hazard ratio. All patients received hemoperfusion. Abbreviations: No IST: No immunosuppressive treatment (Hemoperfusion alone); IST: Immunosuppressive treatment; MP: Methylprednisolone; CP: Cyclophosphamide; DEX: Dexamethasone.</p

The cumulative rate of mortality among different CHADS2, CHA2DS2 and CCI scores over five years.

<p>The cumulative rate of mortality among different CHADS2, CHA2DS2 and CCI scores over five years.</p

Mortality risk stratified by CHADS2, CHA2DS2, and CCI score categories.

(A) CHADS2 score. (B) CHA2DS2 score. (C) CCI score.</p

Hazard ratios of individual comorbidity of the CHADS2 score for mortality in incident hemodialysis patients.

Hazard ratios of individual comorbidity of the CHADS2 score for mortality in incident hemodialysis patients.</p

Kaplan-Meier survival plot of the MP+CP+DEX subgroup (n = 100) versus the non-IST group (n = 1046, log rank test, P<0.001).

<p>Abbreviations: MP: Methylprednisolone; CP: Cyclophosphamide; DEX: Dexamethasone; IST: Immunosuppressive treatment.</p

Receiver operating characteristics curve for CHADS2, CHA2DS2 and CCI in the prediction of mortality in incident hemodialysis patients.

Receiver operating characteristics curve for CHADS2, CHA2DS2 and CCI in the prediction of mortality in incident hemodialysis patients.</p

Baseline characteristics of the incident hemodialysis patients from 2005 to 2009 in Taiwan.

Baseline characteristics of the incident hemodialysis patients from 2005 to 2009 in Taiwan.</p

Treatment effects of different immunosuppressive regimens in paraquat-poisoned patients with hemoperfusion treatment.

<p>Cox regression analysis of mortality rates among different treatment groups, adjusted for age and sex, was used to calculate the hazard ratio. Abbreviations: No IST: No immunosuppressive treatment (Hemoperfusion alone); IST: Immunosuppressive treatment; MP: Methylprednisolone; CP: Cyclophosphamide; DEX: Dexamethasone.</p